- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts | 2 | Seeking Alpha | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Raymond James initiates MapLight stock with strong buy on drug trial | 1 | Investing.com | ||
| Mi | MapLight Therapeutics beruft zwei neue Direktoren in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| Mi | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Changes to Board of Directors | 140 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering... ► Artikel lesen | |
| Di | MapLight Therapeutics stock maintained at Buy by H.C. Wainwright | 1 | Investing.com | ||
| Mo | MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents | 1 | Benzinga.com | ||
| Mo | H.C. Wainwright reiterates MapLight Therapeutics stock rating on muscarinic mechanism potential | 2 | Investing.com | ||
| Mo | MapLight Therapeutics Says IRIS Phase 2 Trial Did Not Meet Its Primary Endpoint; Stock Down 10.5% | 1 | RTTNews | ||
| Mo | MapLight Therapeutics, Inc.: MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder | 166 | GlobeNewswire (Europe) | The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-I... ► Artikel lesen | |
| 18.06. | MapLight Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Stifel raises MapLight Therapeutics price target on drug potential | 1 | Investing.com | ||
| 01.06. | Stifel hebt Kursziel für MapLight Therapeutics wegen Medikamentenpotenzial an | 2 | Investing.com Deutsch | ||
| 21.05. | MapLight Therapeutics: Craig-Hallum startet Coverage mit Kaufempfehlung und 54 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 21.05. | Craig-Hallum initiates MapLight Therapeutics stock with buy rating | 3 | Investing.com | ||
| 15.05. | MapLight Therapeutics, Inc. GAAP EPS of -$1.34 | 1 | Seeking Alpha | ||
| 14.05. | MapLight Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | MapLight completes enrollment in two phase 2 CNS trials | 2 | Investing.com | ||
| 01.05. | MapLight schließt Rekrutierung für zwei zentrale ZNS-Studien ab | 1 | Investing.com Deutsch | ||
| 01.05. | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results | 255 | GlobeNewswire (Europe) | Enrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2... ► Artikel lesen | |
| 08.04. | MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst | 3 | Benzinga.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 108,12 | 0,00 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| BICARA THERAPEUTICS | 26,870 | 0,00 % | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | 0,00 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | 0,00 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | +0,05 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,15 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | 0,00 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | 0,00 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen | |
| QIAGEN | 34,315 | -0,59 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,445 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,720 | 0,00 % | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | ||
| PROKIDNEY | 1,830 | 0,00 % | ProKidney Appoints Kenneth Locke as Chief Technical Officer | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| HUMACYTE | 0,709 | 0,00 % | Humacyte, Inc: Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was... ► Artikel lesen |
MAPLIGHT THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,66 % bei einem Aktienkurs von 33,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.